Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data.
PMID: 24128595 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 12, 2013 Category: Cancer & Oncology Authors: Jain P, Kantarjian H, Estey E, Pierce S, Cortes J, Lopez-Berestein G, Ravandi F Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission.
Abstract INTRODUCTION: Surveillance imaging with computed tomography (CT) or positron emission tomography with CT (PET/CT) is commonly used in practice in patients with non-Hodgkin lymphoma (NHL) who are in remission after front-line therapies. We aimed to determine the utility of routine imaging for detecting first relapse in patients with NHL in complete remission (CR) after first-line therapies. PATIENTS AND METHODS: We retrospectively analyzed patients with NHL who achieved CR after first-line therapies and then subsequently had disease relapse. We evaluated whether the relapse was detected solely by surv...
Source: Clinical Lymphoma and Myeloma - October 10, 2013 Category: Cancer & Oncology Authors: Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma.
CONCLUSION: Treatment with VTEPA for R/R HL is feasible with manageable side effects. With a high ORR, the PFS and OS for this group of patients suggest that VTEPA is a promising regimen for HL patients in whom previous lines of therapy have failed. PMID: 24094894 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 2, 2013 Category: Cancer & Oncology Authors: Sinha R, Shenoy PJ, King N, Lechowicz MJ, Bumpers K, Hutcherson D, Arellano M, Langston A, Kaufman J, Heffner LT, Waller EK, Nooka A, Flowers CR, Lonial S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
CONCLUSIONS: Given that evidence suggests achievement of an early response is predictive of improved long-term outcomes, earlier use of these compounds may lead to more rapid, deeper responses corresponding with improvements in patient outcome. Although future studies will benefit from more uniform definitions of end points and methods of analysis, data from published studies of first-line BCR-ABL inhibitor treatment for patients with newly diagnosed CML-CP support the use of dasatinib or nilotinib in place of imatinib. PMID: 24095296 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - October 1, 2013 Category: Cancer & Oncology Authors: Jabbour E, Lipton JH Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure.
CONCLUSION: Patients with higher-risk MDS in whom azacitidine treatment has failed have a poor prognosis and low probability of response to salvage treatments. The standard of care after azanucleoside failure should be enrollment in clinical trials. PMID: 24054159 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 17, 2013 Category: Cancer & Oncology Authors: Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS Tags: Clin Lymphoma Myeloma Leuk Source Type: research

A Retrospective Analysis of Peripheral T-Cell Lymphoma Treated With the Intention to Transplant in the First Remission.
CONCLUSION: Our results support consolidation of first CR with transplantation. The addition of etoposide did not improve outcomes. Baseline IPI and interim response to CHOP can predict outcomes and guide decisions about transplantation in first CR in PTCL. Randomized trials are necessary to confirm the efficacy of this approach. PMID: 24035712 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 11, 2013 Category: Cancer & Oncology Authors: Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, Zelenetz A, Matasar MJ, Sauter C, Goldberg J, Horwitz SM Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Primary Cutaneous Gamma-Delta T-Cell Lymphoma With Marked Pagetoid Epidermotropism Shortly After Allogeneic Stem Cell Transplantation.
PMID: 24035713 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 11, 2013 Category: Cancer & Oncology Authors: Bautista-Quach MA, Tong T, Nademanee A, Huang Q Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Multiple Myeloma International Staging System: "Staging" or Simply "Aging" System?
Multiple Myeloma International Staging System: "Staging" or Simply "Aging" System? Clin Lymphoma Myeloma Leuk. 2013 Sep 11; Authors: Bataille R, Annweiler C, Beauchet O Abstract Because of the wide variation in multiple myeloma (MM) survival, numerous studies have focused over the past 40 years on the biological and cytogenetic prognostic values in MM patients. Since 2005, the MM International Staging System (ISS) has recognized the combination of beta-2 microglobulin (β2M) with serum albumin (SA) concentrations as the most simple and potent combination to determine the prognosis i...
Source: Clinical Lymphoma and Myeloma - September 11, 2013 Category: Cancer & Oncology Authors: Bataille R, Annweiler C, Beauchet O Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders.
CONCLUSION: The use of aggressive chemoimmunotherapy in combination with the withdrawal of immunosuppression approach yields excellent results and should be prospectively studied in a multiinstitutional setting. PMID: 24035715 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 11, 2013 Category: Cancer & Oncology Authors: Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patients With Acute Myeloid Leukemia.
CONCLUSIONS: There is no correlation between NPM1 mutations and CXCR4 or pCXCR4 expression, suggesting that the CXCR4 and NPM pathways act independently in adult AML. PMID: 24035716 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 11, 2013 Category: Cancer & Oncology Authors: Konoplev S, Lin P, Yin CC, Lin E, Nogueras González GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Fatal Splenic Rupture in a Previously Undiagnosed Multiple Myeloma: Morphological, Immunophenotypical and Molecular Cytogenetic Analyses.
PMID: 24034870 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 10, 2013 Category: Cancer & Oncology Authors: Magnoli F, Freguia S, Bernasconi B, Campiotti L, Oldrini R, Facco C, Sessa F, Uccella S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Burkitt Lymphoma in Pregnancy: Two Cases of Successful Treatment and Continued Fertility; With a Review of the Literature.
PMID: 24021676 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - September 7, 2013 Category: Cancer & Oncology Authors: Hurley P, Linden MA, Peterson B, Blaes A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

MYD88 L265P Somatic Mutation: Its Usefulness in the Differential Diagnosis of Bone Marrow Involvement by B-Cell Lymphoproliferative Disorders.
Conclusions: Although not entirely specific, MYD88 L265P is a useful adjunct for bone marrow diagnosis in separating LPL from other small B-cell lymphomas and plasma cell myeloma. PMID: 23955458 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - August 23, 2013 Category: Cancer & Oncology Authors: Ondrejka SL, Lin JJ, Warden DW, Durkin L, Cook JR, Hsi ED Tags: Am J Clin Pathol Source Type: research

Neuropathy and monoclonal gammopathy.
Abstract The association of neuropathy with monoclonal gammopathy has been known for several years, even if the clinical and pathogenetic relevance of this association is not completely defined. This is not a marginal problem since monoclonal gammopathy is present in 1-3% of the population above 50 years in whom it is often asymptomatic, and in at least 8% of patients is associated with a symptomatic neuropathy, representing one of the leading causes of neuropathy in aged people. Monoclonal gammopathy may result from malignant lymphoproliferative diseases including multiple myeloma or solitary plasmocytoma, Walden...
Source: Clinical Lymphoma and Myeloma - August 18, 2013 Category: Cancer & Oncology Authors: Nobile-Orazio E Tags: Handb Clin Neurol Source Type: research

Candidate genes of Waldenström's macroglobulinemia: current evidence and research.
Candidate genes of Waldenström's macroglobulinemia: current evidence and research. Appl Clin Genet. 2013;6:33-42 Authors: Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A Abstract Waldenström's macroglobulinemia (WM) is a relatively uncommon, indolent malignancy of immunoglobulin M-producing B cells. The World Health Organization classifies it as a lymphoplasmacytic lymphoma and patients typically present with anemia, hepatosplenomegaly and diffuse lymphadenopathies. Historically, the genetic characterization of the disease has been hampered by the relatively low proliferative rate of ...
Source: Clinical Lymphoma and Myeloma - August 18, 2013 Category: Cancer & Oncology Authors: Bianchi G, Sacco A, Kumar S, Rossi G, Ghobrial I, Roccaro A Tags: Appl Clin Genet Source Type: research

Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
iel L Abstract Peripheral blood stem cells (PBSCs) are preferred source of hematopoietic stem cells for autologous transplantation. Mobilization of PBSCs using chemotherapy and/or granulocyte colony-stimulating factor (G-CSF) however fails in around 20%. Combining G-CSF with plerixafor increases the mobilizations success. We compared cost-effectiveness of following schemes: the use of plerixafor "on demand" (POD) during the first mobilization in all patients with inadequate response, the remobilization with plerixafor following failure of the first standard mobilization (SSP), and the standard (re)mobili...
Source: Clinical Lymphoma and Myeloma - August 7, 2013 Category: Cancer & Oncology Authors: Aleš T, Veronika V, Zdeněk K, Daniel L Tags: J Clin Apher Source Type: research

Hepatosplenic γδ T-cell Lymphoma: An Overview.
Hepatosplenic γδ T-cell Lymphoma: An Overview. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):360-9 Authors: Visnyei K, Grossbard ML, Shapira I Abstract Peripheral T-cell lymphomas are a heterogeneous group of lymphoid malignancies. Among these, hepatosplenic γδ T-cell lymphoma (HTCL) represents an aggressive and treatment-resistant subgroup for which new avenues of treatment are critically needed. HTCL is characterized by primary extranodal distribution of the malignant cells with typical intrasinusoidal infiltration of the liver, spleen, and bone marrow, which results in hepatosp...
Source: Clinical Lymphoma and Myeloma - July 28, 2013 Category: Cancer & Oncology Authors: Visnyei K, Grossbard ML, Shapira I Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities.
CONCLUSION: These results highlight the possibility of targeted therapies affecting the genes located on this chromosome (cyclin D, cyclin D2, cyclin-dependent kinase 2, and cyclin-dependent kinase 4). PMID: 23876845 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 28, 2013 Category: Cancer & Oncology Authors: Jimenez-Zepeda VH, Chng WJ, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Rituximab-Induced Acute Severe Thrombocytopenia: A Case Series in Patients With Mantle Cell Lymphoma.
PMID: 23870855 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 16, 2013 Category: Cancer & Oncology Authors: K Sadashiv S, Rao R, Fazal S, Lister J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Dissecting Karyotypic Patterns in Non-Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution.
CONCLUSION: Accumulation of genetic aberrations in NH-MM above a threshold results in malignant transformation. PMID: 23856591 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 12, 2013 Category: Cancer & Oncology Authors: Jimenez-Zepeda VH, Braggio E, Fonseca R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Emergence of Cunninghamella As a Pathogenic Invasive Mold Infection in Allogeneic Transplant Recipients.
PMID: 23850285 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - July 10, 2013 Category: Cancer & Oncology Authors: Strasfeld L, Espinosa-Aguilar L, Gajewski JL, Stenzel P, Pimentel A, Mater E, Maziarz RT Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Simultaneous Presentation of Waldenström Macroglobulinemia and Multiple Myeloma: Multidisciplinary Diagnosis, Treatment and 30-Month Follow-up.
We report the case of a 75-year Caucasian female patient, with a silent clinical history, who presented with anemia and two different monoclonal proteins (IgMκ and IgGκ). The trephine biopsy showed the presence of a dual population, represented by small lymphoplasmacytoid cells and by plasma cells, which infiltrated the bone marrow with a clearly different pattern. Both immunohistochemistry and flow cytometry demonstrated the biclonal origin such neoplastic cells, since lymphoplasmacytoid cells resulted IgMκ while plasma cells were IgGκ. This biclonal pattern was further confirmed by the demonstrati...
Source: Clinical Lymphoma and Myeloma - June 30, 2013 Category: Cancer & Oncology Authors: Carulli G, Ciancia EM, Azzarà A, Ottaviano V, Grassi S, Ciabatti E, Ferreri MI, Rocco M, Marini A, Petrini M Tags: J Clin Exp Hematop Source Type: research

Metastatic Splenic Angiosarcoma Presenting With Thrombocytopenia and Bone Marrow Fibrosis Mimicking Idiopathic Thrombocytopenic Purpura and Primary Myelofibrosis: A Diagnostic Challenge.
PMID: 23800601 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 22, 2013 Category: Cancer & Oncology Authors: Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, Medeiros LJ, Lin P Tags: Clin Lymphoma Myeloma Leuk Source Type: research

CD4(-)/CD8(-) Variant of T-Cell Large Granular Lymphocytic Leukemia or Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Dilemma.
PMID: 23800602 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 22, 2013 Category: Cancer & Oncology Authors: Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJ Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.
Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk. 2013 Jun 19; Authors: Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G Abstract BACKGROUND: After the World Health Organization (WHO) changed the definition of acute myeloid leukemia (AML) to ≥ 20% blasts, the International Working Group (IWG) response criteria for myelodysplasia were updated. This retrospectiv...
Source: Clinical Lymphoma and Myeloma - June 19, 2013 Category: Cancer & Oncology Authors: Jabbour E, Kantarjian H, O'Brien S, Kadia T, Malik A, Welch MA, Teng A, Cortes J, Ravandi F, Garcia-Manero G Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval.
Abstract Homoharringtonine/omacetaxine is a unique agent with a long history of research development. It has been recently approved by the Food and Drug Administration for the treatment of chronic myeloid leukemia after failure of 2 or more tyrosine kinase inhibitors. Research with this agent has spanned over 40 years, with many instructive lessons to cancer research, which are summarized in this review. PMID: 23790799 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 19, 2013 Category: Cancer & Oncology Authors: Kantarjian HM, O'Brien S, Cortes J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy.
Abstract Multiple myeloma (MM) arises from abnormal proliferation and survival (ie, a high proliferative index and a low apoptotic index) of mature immunoglobulin-producing plasma cells in the bone marrow. Development of novel therapeutic options, such as proteasome inhibitors and immunomodulatory agents (IMiDs), has improved treatment outcomes. However, patients often develop relapsed and refractory MM, thus requiring alternative treatment approaches. Histone acetyltransferases and histone deacetylases (HDACs) control the acetylation status of proteins and affect a broad array of physiologic processes (eg, cell c...
Source: Clinical Lymphoma and Myeloma - June 17, 2013 Category: Cancer & Oncology Authors: Kaufman JL, Fabre C, Lonial S, Richardson PG Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib.
CONCLUSION: Omacetaxine produced clinically meaningful responses with acceptable tolerability in patients with CML-CP previously treated with 2 or more TKIs. PMID: 23787123 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 17, 2013 Category: Cancer & Oncology Authors: Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Antibody-drug conjugates in hematologic malignancies.
Abstract Antibody-drug conjugates (ADCs) are agents composed of a monoclonal antibody linked to cytotoxic molecules. By specifically delivering cytotoxic agents to cells expressing surface antigens of interest, ADC technology allows for the targeted use of highly toxic agents resulting in increased efficacy against malignant cells and decreased damage to normal tissue. Effector agents can be small molecules, radioisotopes, proteins, or bacterially derived toxins. Over the past several decades, ADCs have been evaluated in a variety of preclinical models of hematologic malignancies, as well as early-phase clinical t...
Source: Clinical Lymphoma and Myeloma - June 16, 2013 Category: Cancer & Oncology Authors: Leslie LA, Younes A Tags: Am Soc Clin Oncol Educ Book Source Type: research

Novel approaches to treatment of double-refractory multiple myeloma.
Abstract Multiple myeloma (MM) refractory to both proteasome inhibitors and immunomodulatory agents (IMiDs; double-refractory myeloma) has a poor prognosis. With the more frequent use of these agents as part of initial therapy, and then in the maintenance setting until disease progression, such drug resistance is an emerging problem of great significance. New therapeutic strategies are clearly needed for this patient population, including the development of more potent agents within existing antimyeloma drug classes, exploration of rational combinations of both novel and conventional drugs, and validation of new m...
Source: Clinical Lymphoma and Myeloma - June 16, 2013 Category: Cancer & Oncology Authors: Lee HC, Shah JJ, Orlowski RZ Tags: Am Soc Clin Oncol Educ Book Source Type: research

Developing novel strategies to target B-cell malignancies.
Abstract In the past several years we have seen the identification and validation of several key pathways that drive malignant B-cell development. In addition, the effect nonmalignant effector cells within the immune microenvironment have on tumor survival, proliferation, and possibly chemotherapy resistance is increasingly understood. Although there is still much to be learned, this improved understanding combined with rapid advances in medicinal chemistry focusing on structure-based drug design have resulted in a shift in the development of new agents away from traditional chemotherapy to more selective agents t...
Source: Clinical Lymphoma and Myeloma - June 16, 2013 Category: Cancer & Oncology Authors: Fowler N, Oki Y Tags: Am Soc Clin Oncol Educ Book Source Type: research

Sequential Lymphomas or Clonally Unrelated Richter Syndrome of Chronic Lymphocytic Leukemia Into Mantle Cell Lymphoma.
PMID: 23763914 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Jain P, Le X, Young KH, Patel KP, Wang S, Pei L, Barron LL, Abruzzo L, O'Brien S Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy.
CONCLUSION: Elderly AML patients with NPM1-MUT/FLT3-WT genotype have significantly improved outcomes compared with patients with other NPM1/FLT3 genotypes when treated with cytotoxic chemotherapy. PMID: 23763915 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Daver N, Dumlao TL, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Thoracic t(9;22)-Positive Granulocytic Sarcoma as Initial Presentation of Chronic Myeloid Leukemia.
PMID: 23763916 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Mitchell M, Itani D, Gerber J, Ghosh N, Gojo I, Zeidan A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML.
CONCLUSION: The MTD of 1000 mg barasertib in combination with LDAC in older patients with AML was associated with acceptable tolerability and preliminary anti-AML activity. PMID: 23763917 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Expectations of Serious Adverse Events at the End of Life of Patients With Acute Myeloid Leukemia Who Receive Salvage Therapy.
CONCLUSIONS: Baseline expectations of serious AEs at the end of life of patients with AML undergoing ST were established. The AE profiles of new investigational interventions or therapies could be compared with what would be expected in such circumstances from the combined effect of disease progression, expected complications of the AML therapy, and therapies delivered in previous historical contexts. PMID: 23763918 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Upfront Autologous Stem Cell Transplantation for Untreated High-Risk Diffuse Large B-Cell Lymphoma in Patients Up to 60 Years of Age.
CONCLUSION: These results suggest that adding rituximab to upfront HDT/ASCT is feasible and can improve the outcome in untreated patients with poor-prognosis DLBCL. In the future, upfront HDT/ASCT should be more extensively evaluated in clinical trials. PMID: 23763919 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Takasaki H, Hashimoto C, Fujita A, Matsumoto K, Taguchi J, Kuwabara H, Yamazaki E, Koharazawa H, Fujita H, Fujisawa S, Ishii Y, Yamamoto W, Motomura S, Tomita N, Ishigatsubo Y, Sakai R Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
CONCLUSION: Single-agent nanomolecular liposomal annamycin appears to be well tolerated, and shows evidence of clinical activity as a single agent in refractory adult ALL. PMID: 23763920 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Wetzler M, Thomas DA, Wang ES, Shepard R, Ford LA, Heffner TL, Parekh S, Andreeff M, O'Brien S, Kantarjian HM Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies.
CONCLUSION: Alternate-day oral dosing of PF-04929113 at 74 mg/m(2) for 21/28 days was generally well tolerated with reversible toxicity. The responses observed in myeloma and lymphoma patients are encouraging. PMID: 23763921 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Reddy N, Voorhees PM, Houk BE, Brega N, Hinson JM, Jillela A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Aggressive Behavior and Elevated Lactate Dehydrogenase at Baseline Confer Inferior Prognosis in Patients With Primary Cutaneous Lymphoma.
CONCLUSION: The study data suggest that aggressive behavior and elevated LDH levels at baseline were predictive factors for poor PFS and OS, which supports the need for immediate treatment of those patients. PMID: 23763922 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Liu WP, Song YQ, Zheng W, Wang XP, Ding N, Zhu J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma.
Abstract Most patients with mantle cell lymphoma (MCL) relapse within a few years of treatment. Conventional agents provide little benefit, thus identification of new therapies is critical to improve patient outcomes. Temsirolimus, an inhibitor of mammalian target of rapamycin, is an effective, well-tolerated option authorized in Europe for treatment of patients with relapsed/refractory MCL. Intravenous temsirolimus has been extensively studied in MCL and has consistently demonstrated single-agent antitumor activity. In the pivotal phase III trial, treatment with temsirolimus 175 mg weekly for 3 weeks followed by ...
Source: Clinical Lymphoma and Myeloma - June 10, 2013 Category: Cancer & Oncology Authors: Coiffier B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Sequential Signs of Palpitation, Bloody Multiple Cavity Membrane Effusion, and Myocardial Infarction: A Case Report of Multiple Myeloma and a Literature Review.
PMID: 23747078 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 5, 2013 Category: Cancer & Oncology Authors: Zhang C, Zhang X, Chen XH Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Sequential Occurrence of a Splenic Marginal Zone Lymphoma, Extranodal MALT Lymphoma, and Hodgkin Lymphoma.
ade J PMID: 23747079 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 5, 2013 Category: Cancer & Oncology Authors: Zeidan A, Faltas B, Forde P, Subhawong A, Bello C, Bolaños-Meade J Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Successful Treatment of Bing-Neel Syndrome Using Intrathecal Chemotherapy and Systemic Combination Chemotherapy Followed by BEAM Auto-Transplant: A Case Report and Review of Literature.
Successful Treatment of Bing-Neel Syndrome Using Intrathecal Chemotherapy and Systemic Combination Chemotherapy Followed by BEAM Auto-Transplant: A Case Report and Review of Literature. Clin Lymphoma Myeloma Leuk. 2013 Jun 5; Authors: Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B PMID: 23747080 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 5, 2013 Category: Cancer & Oncology Authors: Abdallah AO, Atrash S, Muzaffar J, Abdallah M, Kumar M, Van Rhee F, Barlogie B Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma.
Abstract BACKGROUND: Although sIL-2R level has a prognostic value in patients with diffuse large B-cell lymphoma, its clinical role in patients with follicular lymphoma has not been determined. PATIENTS AND METHODS: We reviewed data on 70 patients diagnosed with follicular lymphoma. RESULTS: Ann Arbor stage was I, II, III, and IV in 6, 9, 17, and 38 patients, respectively, and grade classification according to the World Health Organization criteria was 1, 2, 3A, 3B, and not available in 28, 15, 11, 4, and 12 patients, respectively. sIL-2R at diagnosis was significantly correlated with Ann Arbor stages (P 
Source: Clinical Lymphoma and Myeloma - June 5, 2013 Category: Cancer & Oncology Authors: Yoshizato T, Nannya Y, Imai Y, Ichikawa M, Kurokawa M Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
PMID: 23730878 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 1, 2013 Category: Cancer & Oncology Authors: Zhang L, Newberry KJ, Wang M Tags: Expert Rev Clin Immunol Source Type: research

Ofatumumab in Rituximab-Refractory Autoimmune Hemolytic Anemia Associated With Chronic Lymphocytic Leukemia: A Case Report and Review of Literature.
PMID: 23726016 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 29, 2013 Category: Cancer & Oncology Authors: Nader K, Patel M, Ferber A Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports.
PMID: 23726017 [PubMed - as supplied by publisher] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 29, 2013 Category: Cancer & Oncology Authors: Broccoli A, Derenzini E, Pellegrini C, Narducci R, Stefani G, Casadei B, Argnani L, Zinzani PL Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure.
Abstract Objective: Circulating endothelial cells (CECs) in patients with hematological malignancies are assessed as a noninvasive marker of angiogenesis. The aim of this study was to evaluate the numbers of CECs and their subsets during mobilization of hematopoietic stem cells. Patients and methods: Thirty-eight patients were enrolled to the study (19 females and 19 males) at median age of 56.5 years. The group consisted of patients with multiple myeloma (26), lymphoma (10), and acute myeloid leukemia (2). Blood samples were collected before chemotherapy (0), 1 day after chemotherapy (Cht+1), on the day G-CSF com...
Source: Clinical Lymphoma and Myeloma - May 16, 2013 Category: Cancer & Oncology Authors: Szmigielska-Kapłon A, Krawczyńska A, Czemerska M, Pluta A, Cebula-Obrzut B, Szmigielska K, Smolewski P, Robak T, Wierzbowska A Tags: J Clin Apher Source Type: research

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies.
CONCLUSIONS: BMS-936564/MDX-1338 is a potent CXCR4 antagonist which is efficacious as monotherapy in tumor-bearing mice and is currently in phase I for the treatment of relapsed/refractory AML, NHL, CLL, and multiple myeloma. Clin Cancer Res; 19(2); 357-66. ©2012 AACR. PMID: 23213054 [PubMed - in process] (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - January 15, 2013 Category: Cancer & Oncology Authors: Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, Cohen LJ, Korman AJ, Cardarelli PM Tags: Clin Cancer Res Source Type: research